ClinicalTrials.gg
Not yet recruitingNCT07854197Updated Oct 8, 2026

Effect of Remimazolam on Hypoxemia and/or Hypotension in Prostate Biopsy

An interventional study of Using remimazolam for sedation during prostate biopsy and Administer 1.5mg/kg of propofol for sedation in Prostate Biopsy and Sedation Complication, sponsored by RenJi Hospital. Not yet recruiting. Open to male participants aged 65 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by RenJi Hospital · Not applicable, Interventional, and Other

How we know

Updated Oct 2, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,146
Allocation
Randomized
Ages
65 Years to 80 Years
Sex
Male
01

Study summary

This study aims to investigate whether remimazolam, a novel benzodiazepine sedative, can reduce the composite incidence of hypotension and hypoxemia during prostate biopsy in elderly patients compared with propofol. This study is a multicenter prospective randomized controlled trial.Participants will be recruited from five centers: Renji Hospital (Shanghai), Sun Yat-sen University Cancer Center, Zhongda Hospital (Nanjing), Shenzhen Hospital of the Cancer Hospital (CAMS), and Liaoning Fangda General Hospital.Baseline data will be collected for all participants, including demographic information, comorbidities, concurrent medication use, and vital signs.A total of 1,146 eligible participants will be randomized in a 1:1 ratio to receive either remimazolam (experimental group) or propofol (control group). Intraoperative hypoxemia and hypotension will be recorded as the primary outcomes. Secondary outcomes will include other sedation-related adverse events and patient satisfaction, which will be evaluated to comprehensively assess the efficacy and safety profile of remimazolam.

02

Conditions studied

  • Prostate Biopsy
  • Sedation Complication
03

In context

Lead sponsor

RenJi Hospital is the lead sponsor of 551 studies on the registry; 248 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years to 80 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 65 years old ≤ age ≤ 80 years old;
  • undergo sedated transperineal prostate ;
  • 18.5kg/m2 ≤ \<30kg/m2
  • ASA ≤ III;
  • voluntarily participate in the research and sign the form.

Exclusion criteria

Exclusion Criteria:

  • expected difficult airway;
  • hypertension (with a systolic blood pressure of ≥ 180 mmHg and/or a diastolic blood pressure of ≥ 100 mmHg), or with a systolic blood pressure of ≤ 90 mmHg;
  • baseline SpO2 \< 93%, or RR \< 10 b/m or more than 24 b/m, or a clear diagnosis of obstructive sleep apnea syndrome (OSAS);
  • diagnosed with heart disease (heart failure, angina, myocardial infarction, arrhythmia, etc.);
  • diagnosed with lung diseases (asthma, bronchitis, , pulmonary bullae, pulmonary embolism, pulmonary oedema, etc.);
  • hepatic dysfunction ( and/or alanine aminotransferase ≥ 2.5 times the value, total ≥ 1.5 times the upper limit of normal value);
  • renal insufficiency (creatinine level ≥ 1.5 times the upper limit of the normal range);
  • cognitive or mental disorders;
  • history of drug and/or alcohol abuse within 2 years before initiating the screening period; average daily alcohol consumption of >2 units of alcohol (1 unit = 360 mL beer or 45 mL liquor with 40% alcohol content or 150 mL grapes liquor);
  • allergies or to benzodiazepines, opioids, propofol;
  • use of benzodiazepines, propofol and opioid drugs within the past three months;
  • participated in other drug clinical trials in the past 3 months;
  • investigator's judgment as an unsuitable participant.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
1,146 participants (estimated)

Study arms

  • Experimental
    Remimazolam group

    Administer 0.2mg/kg of remimazolam for sedation

    Drug: Using remimazolam for sedation during prostate biopsy

  • Active comparator
    Propofol group

    Administer 1.5mg/kg of propofol for sedation

    Drug: Administer 1.5mg/kg of propofol for sedation

Interventions

  • DrugUsing remimazolam for sedation during prostate biopsy

    Administer 0.2mg/kg remimazolam, with the infusion time exceeding 10 seconds. Once the subject reaches a sufficient level of sedation (MOAA/S score ≤ 1), the operating doctor performs local infiltration anesthesia at the perineal puncture site with 5-10ml of 2% lidocaine, and then begins the prostate puncture procedure.

  • DrugAdminister 1.5mg/kg of propofol for sedation

    Administer 1.5mg/kg of propofol, with the injection time exceeding 10 seconds. Once the subject reaches a sufficient level of sedation (MOAA/S score ≤ 1), the operating doctor performs local infiltration anesthesia at the perineal puncture site with 2% lidocaine, and then begins the prostate puncture procedure.

06

What researchers measure

Primary outcomes

  1. The incidence of composite adverse events during sedation

    Composite adverse events are defined as the occurrence of hypoxemia and/or hypotension. Hypoxemia is defined as SpO₂ \< 90%, and hypotension is defined as a mean arterial pressure (MAP) ≤ 70 mmHg or a decrease of more than 30% from baseline.

    Time frame: During the sedation period of the prostate biopsy procedure

Secondary outcomes

  1. The incidence of hypoxia during the sedation process.

    SpO2 \< 90%

    Time frame: During the sedation period of the prostate biopsy procedure

  2. The incidence of severe hypoxia during the sedation process.

    SPO2 is between 75% and 90% for a duration of ≥ 60 seconds, or SPO2 is less than 75%

    Time frame: During the sedation period of the prostate biopsy procedure

  3. The incidence of subclinical respiratory depression during the sedation process.

    90% ≤ SpO2 \< 95%

    Time frame: During the sedation period of the prostate biopsy procedure

  4. The incidence of hypotension during the sedation period .

    Hypotension is defined as a mean arterial pressure (MAP) ≤ 70 mmHg or a decrease of more than 30% from baseline.

    Time frame: During the sedation period for prostate biopsy surgery

  5. Success rate of sedation

    Time frame: During the sedation period of the prostate biopsy procedure

  6. Induction Time

    The time from the first administration of sedatives (remiamorol or propofol) to when the MOAA/S score reaches ≤1 indicating a sedated state

    Time frame: During the sedation period of the prostate biopsy procedure

  7. Awakening time

    The time from the cessation of drug administration to when the MOAA/S score remained at 5 for three consecutive times

    Time frame: During the recovery period of the prostate biopsy procedure

  8. The incidence rate of injection pain

    Time frame: During the sedation period of the prostate biopsy procedure

  9. The incidence of patient movement during the procedure.

    Time frame: During the sedation period of the prostate biopsy procedure

  10. Operator satisfaction with the conduct of the prostate biopsy procedure

    After the prostate puncture procedure, ask about the satisfaction level with the operating doctor. Assess using a Numerical Rating Scale ranging from 0 to 10, where 1 to 3 means "dissatisfied," 4 to 6 means "satisfied," and 7 to 10 means "very satisfied."

    Time frame: During the whole prostate biopsy procedure

  11. Patient satisfaction

    Before the patient leaves the recovery room after fully waking up, ask about the patient's satisfaction level. Assess using a Numerical Rating Scale ranging from 0 to 10, where 1 to 3 means "dissatisfied," 4 to 6 means "satisfied," and 7 to 10 means "very satisfied."

    Time frame: During the whole prostate biopsy procedure

  12. Visual Analogue Scale (VAS) score 15 minutes after prostate biopsy

    Perform a pain assessment using a Visual Analogue Scale (VAS) 15 minutes after the surgery, ranging from 0 to 10, where 0 indicates no pain and 10 indicates the most severe pain the patient has ever experienced.

    Time frame: 15 minutes after prostate biopsy

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Jun 2027, 8 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2026
First posted
Oct 2, 2026
StartEst.
Oct 8, 2026
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jul 1, 2027
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Secondary outcomes
3 description edited
What changed in the outcomes
  • DescriptionOperator satisfaction with the conduct of the prostate biopsy procedure: how it is measured was reworded
  • DescriptionPatient satisfaction: how it is measured was reworded
  • DescriptionVisual Analogue Scale (VAS) score 15 minutes after prostate biopsy: how it is measured was reworded
Oct 8, 2026
Registered
First appeared on the registry
Oct 2, 2026
Show all 2 updates
  1. Oct 8, 2026
    Secondary outcomes 3 description edited
    What changed in the outcomes
    • DescriptionOperator satisfaction with the conduct of the prostate biopsy procedure: how it is measured was reworded
    • DescriptionPatient satisfaction: how it is measured was reworded
    • DescriptionVisual Analogue Scale (VAS) score 15 minutes after prostate biopsy: how it is measured was reworded
    + 1 other change: responsible party
  2. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07854197
Lead sponsor
RenJi Hospital
Responsible party
Jie Tian (Principal Investigator, RenJi Hospital) — Principal investigator
First posted
Oct 2, 2026
Start date
Oct 8, 2026 (estimated)
Primary completion
Jun 30, 2027 (estimated)
Completion
Jul 1, 2027 (estimated)
Last update
Oct 8, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion